Breckenridge Pharmaceutical, Inc. has entered into a multi-product marketing agreement with development and manufacturing partner Gland Pharma Limited for seven (7) injectable products.

Under the terms of this agreement, Breckenridge will market and distribute the products under its label in the United States. The deal includes six approved ANDA's and one tentatively-approved ANDA. The products cover a wide range of indications.  This deal further showcases Breckenridge's entry into the Institutional market and expanding injectable portfolio.

Breckenridge Pharmaceutical, Inc. is a privately-held own label distributor that performs pharmaceutical research and development as well as marketing and distribution in the US.

Established in 1978 and based in Hyderabad, Gland develops and manufactures generic injectables for use in nearly 90 countries on five continents, with a focus on the Indian and US markets.